Medical cannabis is a massively growing market in Europe.
In 2019 the European Medicines agency (EMA) authorized the first medicinal product containing the active substance cannabidiol (CBD) for a rare form of childhood epilepsy, but that remains the exception.
No other EU-wide marketing authorisation has been granted for cannabinoid-containing medicinal products. This has opened up a once in a generation opportunity to make changes that will lead to much more effective and cost-efficient pharmacovigilance.
Cannabis is a massive opportunity, but supplying the different European markets can be a challenge.
To help address the challenge, Arriello has produced this country-by-country guide to the patchwork of regulations across Europe.